In this very special episode of MarketFoolery, host Chris Hill and analyst Matt Argersinger talk about a few of the stock market’s biggest and most mind-altering stories. Constellation Brands (NYSE:STZ), the alcoholic beverage giant behind Corona and Svedka, just bet $4 billion on Canadian cannabis producer Canopy Growth (NYSE:CGC). Constellation shares plummeted 9% on the news. What gives? With recreational marijuana laws finalizing in October, Canopy can only go up from here, right? Well, not quite.
Matt explains the risks of investing in marijuana companies, and why investors hated Constellation’s move so much. Also, Macy’s (NYSE:M) put in a pretty good quarter, but its stock still fell a whopping 13% on the report. The guys discuss how the U.S. markets are soaring while international ones have struggled year to date, as well as reports that behind the scenes, the private markets are getting frothy. They end the show with a story about Bud Light dropping fridges of free beer all over Cleveland…with a catch. Click play and find out more.
Hot Canadian Stocks To Own For 2019: Cross Timbers Royalty Trust(CRT)
Advisors’ Opinion:
- [By Ethan Ryder]
Cross Timbers Royalty Trust (NYSE:CRT) announced a dividend on Tuesday, August 21st, NASDAQ reports. Stockholders of record on Friday, August 31st will be paid a dividend of 0.108 per share by the oil and gas company on Monday, September 17th. The ex-dividend date of this dividend is Thursday, August 30th.
- [By Ethan Ryder]
News stories about Cross Timbers Royalty Trust (NYSE:CRT) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cross Timbers Royalty Trust earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the oil and gas company an impact score of 47.0297657024049 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Hot Canadian Stocks To Own For 2019: ZIOPHARM Oncology Inc(ZIOP)
Advisors’ Opinion:
- [By Logan Wallace]
A number of hedge funds have recently bought and sold shares of ZIOP. MSD Partners L.P. increased its position in ZIOPHARM Oncology by 222.1% during the 4th quarter. MSD Partners L.P. now owns 10,986,258 shares of the biotechnology company’s stock valued at $20,544,000 after buying an additional 7,575,758 shares in the last quarter. FMR LLC bought a new position in ZIOPHARM Oncology during the 3rd quarter valued at approximately $1,647,000. Ibex Investors LLC bought a new position in ZIOPHARM Oncology during the 4th quarter valued at approximately $755,000. Bank of America Corp DE increased its position in ZIOPHARM Oncology by 198.1% during the 2nd quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 201,063 shares in the last quarter. Finally, Old West Investment Management LLC increased its position in ZIOPHARM Oncology by 784.7% during the 4th quarter. Old West Investment Management LLC now owns 223,319 shares of the biotechnology company’s stock valued at $417,000 after buying an additional 198,077 shares in the last quarter. 40.12% of the stock is owned by institutional investors.
WARNING: “ZIOPHARM Oncology (ZIOP) Stock Price Up 8.9%” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4199573/ziopharm-oncology-ziop-stock-price-up-8-9.html.
ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)
- [By Lisa Levin] Gainers
Oragenics, Inc. (NYSE: OGEN) shares surged 66.67 percent to close at $2.00 on Wednesday after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study.
Sigma Labs, Inc. (NASDAQ: SGLB) shares jumped 49.24 percent to close at $1.97 on Wednesday. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing.
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) rose 34.45 percent to close at $9.21. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating.
Dick's Sporting Goods, Inc. (NYSE: DKS) shares rose 25.82 percent to close at $38.35 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook.
TapImmune, Inc. (NASDAQ: TPIV) rose 24.15 percent to close at $5.09. WBB Securities upgraded TapImmune from Speculative Buy to Buy.
Legacy Reserves LP (NASDAQ: LGCY) jumped 23.3 percent to close at $5.98 on Wednesday.
Summer Infant, Inc. (NASDAQ: SUMR) gained 22.92 percent to close at $1.18 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital.
Cloud Peak Energy Inc. (NYSE: CLD) rose 21.95 percent to close at $4.00.
SpartanNash Co (NASDAQ: SPTN) gained 21.4 percent to close at $22.92 after the company reported upbeat earnings for its first quarter on Tuesday.
Motus GI Holdings, Inc. (NASDAQ: MOTS) rose 17.14 percent to close at $5.40.
Movado Group, Inc. (NYSE: MOV) gained 16.59 percent to close at $49.20 after the company reported better-than-expected Q1 results and raised its guidance.
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) climbed 15.61 percent to close at $8.22. Oramed Pharma disclosed that its patent has been allowed in the US for oral administration of proteins.
Dorian LPG Ltd. (NYSE: LPG) rose 14.89 percent to close at $8.41. Dorian LPG confirmed receipt of unsolicited proposal fr - [By Motley Fool Transcribers]
Ziopharm Oncology Inc (NASDAQ:ZIOP)Q4 2018 Earnings Conference CallMarch 05, 2019, 4:30 p.m. ET
Contents:
Prepared Remarks Questions and Answers Call Participants
Prepared Remarks:Operator
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Ziopharm Oncology (ZIOP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Lisa Levin]
Check out these big penny stock gainers and losers
Losers
Stellar Biotechnologies, Inc. (NASDAQ: SBOT) fell 42 percent to $2.25 in pre-market trading after dropping 31.45 percent on Thursday. Stellar Biotechnologies priced 2.075 million units at price of $2.65 per unit.
Symantec Corporation (NASDAQ: SYMC) shares fell 25.2 percent to $21.82 in pre-market trading. Symantec reported better-than-expected earnings for its fourth quarter, but issued weak second-quarter guidance.
AGM Group Holdings Inc. (NASDAQ: AGMH) shares fell 9.5 percent to $10 in pre-market trading after surging 7.79 percent on Thursday.
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) fell 8.9 percent to $4.11 in pre-market trading after the company posted wider-than-expected Q1 loss.
Redfin Corporation (NASDAQ: RDFN) fell 8.6 percent to $21.00 in pre-market trading after reporting Q1 results.
Geron Corporation (NASDAQ: GERN) fell 8.3 percent to $3.33 in pre-market trading. Geron posted a Q1 loss of $0.04 per share.
Talend S.A. (NASDAQ: TLND) shares fell 6 percent to $56 in pre-market trading after reporting Q1 results.
Flotek Industries, Inc. (NYSE: FTK) fell 5.4 percent to $3.54 in pre-market trading after dropping 2.35 percent on Thursday.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) fell 5.1 percent to $18.95 in pre-market trading after reporting Q1 results.
Yelp Inc. (NYSE: YELP) shares fell 4.9 percent to $45.40 in pre-market trading. Yelp reported stronger-than-expected results for its first quarter on Thursday.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares fell 3.3 percent to $7.50 in pre-market trading after dropping 4.32 percent on Thursday - [By Keith Speights]
Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past, though. Which of these two clinical-stage biotech stocks is the better pick for investors now?
Hot Canadian Stocks To Own For 2019: ING Group, N.V.(ISP)
Advisors’ Opinion:
- [By Stephan Byrd]
Goldman Sachs Group set a €2.90 ($3.37) price target on Intesa Sanpaolo (BIT:ISP) in a report published on Wednesday. The firm currently has a neutral rating on the stock.
- [By Max Byerly]
Intesa Sanpaolo (BIT:ISP) received a €3.00 ($3.53) price target from stock analysts at HSBC in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the stock. HSBC’s target price points to a potential downside of 2.60% from the stock’s current price.
- [By Ethan Ryder]
Intesa Sanpaolo (BIT:ISP) has been given a €2.15 ($2.50) target price by stock analysts at UBS Group in a research note issued on Tuesday, www.boersen-zeitung.de reports. The firm presently has a “neutral” rating on the stock.